• Home
  • About
  • The MDT
  • Science & innovation
    • New Therapies
    • Learning
    • Research & Clinical Trials
  • News & features
    • Features
    • News & Updates
  • Publications
    • General Publications
    • Clinical Guidelines
    • Patient Guidelines
  • Events
  • Contact
National Haemoglobinopathy Panel | NHP Haemoglobinopathy England | Sickle Cell Thalassaemia | Rare Inherited Anaemia UK | NHP Haemoglobinopathy England | Sickle Cell Thalassaemia | Rare Inherited Anaemia UK
National Haemoglobinopathy Panel | NHP Haemoglobinopathy England | Sickle Cell Thalassaemia | Rare Inherited Anaemia UK | NHP Haemoglobinopathy England | Sickle Cell Thalassaemia | Rare Inherited Anaemia UK

National Haemoglobinopathy Panel | NHP Haemoglobinopathy England | Sickle Cell Thalassaemia | Rare Inherited Anaemia UK | NHP Haemoglobinopathy England | Sickle Cell Thalassaemia | Rare Inherited Anaemia UK

  • X
  • LinkedIn
  • Instagram
  • Home
  • About
  • The MDT
  • Science & innovation
    • New Therapies
    • Learning
    • Research & Clinical Trials
  • News & features
    • Features
    • News & Updates
  • Publications
    • General Publications
    • Clinical Guidelines
    • Patient Guidelines
  • Events
  • Contact

New Therapies

New Therapies

Pfizer Shares  Patient Letter re Voxelotor (Oxybryta®) Withdrawal

Posted 21st October 2024

Posted 9 months ago

By Pfizer

Features New Therapies Patient Guidelines Publications

Pfizer Shares Patient Letter re Voxelotor (Oxybryta®) Withdrawal

Pfizer Shares Patient Advice Regarding Immediate Withdrawal of Voxelotor (Oxybryta®)

Read More
Voxelotor (Oxbryta®) Withdrawal - NHP Patient Letter

Posted 10th October 2024

Posted 9 months ago

By NHP Office

Features New Therapies News & Updates Patient Guidelines Publications

Voxelotor (Oxbryta®) Withdrawal - NHP Patient Letter

Following the unforeseen Pfizer withdrawal of Voxelotor (Oxbryta®) Medication for Sickle Cell Disease on 25th September 2024, the NHP provided a letter assist affected Sickle Cell Disorder patients.

Read More
NHS England on Oxbryta (Voxelotor) Withdrawal From the UK Market

Posted 4th October 2024

Posted 10 months ago

By NHS England

General Publications New Therapies Publications

NHS England on Oxbryta (Voxelotor) Withdrawal From the UK Market

NHS England sends a letter to centres regarding the 25.09.2024 withdrawal of Pfizer's Oxbryta (Voxelotor) drug for Sickle Cell Disorder.

Read More
Pfizer Withdraws OXBRYTA ® (Voxelotor) for the treatment of sickle cell disease (SCD)

Posted 25th September 2024

Posted 10 months ago

By NHP Office

Features New Therapies News & Updates

Pfizer Withdraws OXBRYTA ® (Voxelotor) for the treatment of sickle cell disease (SCD)

On 25th September 2024, Pfizer announced its voluntarily withdrawing of all lots of OXBRYTA ® (Voxelotor) for the treatment of sickle cell disease (SCD).

Read More
SOP- Casgevy (Exagamglogene Autotemcel) for Transfusion-dependent Thalassaemia

Posted 9th September 2024

Posted 10 months ago

By NHS England

Clinical Guidelines New Therapies Publications

SOP- Casgevy (Exagamglogene Autotemcel) for Transfusion-dependent Thalassaemia

University College London have produced a Standard Operating Procedure (SOP) for the assessment and work up of exagamglogene autotemcel (Casgevy™) for transfusion-dependent beta-thalassaemia

Read More
Gene-editing therapy, Casgevy, for Transfusion Dependent Thalassaemia

Posted 8th August 2024

Posted 12 months ago

By NHP Office

Features New Therapies News & Updates

Gene-editing therapy, Casgevy, for Transfusion Dependent Thalassaemia

On 08.08.2024 the National Institute for Health and Care Excellence (NICE) approves NHS use of Casgevy ™ [Exagamglogene Autotemcel (‘Exa-Cel’)] for treatment of Transfusion-dependent beta Thalassaemia

Read More
New Therapies Session- ASCAT 2022

Posted 26th January 2022

Posted 3 years ago

By NHP Office

Learning New Therapies

New Therapies Session- ASCAT 2022

View 3 insightful presentations with Q&A from the New Therapies Session at the virtual ASCAT 2022.

Read More

Quick links

Home
About
The MDT
Science & innovation
News & features
Events
Contact

Get in touch

The National Haemoglobinopathy Panel
Women’s and Children’s Academic Health - Kings College London
Becket House
1 Lambeth Palace Rd
London, SE1 7EU

Connect

  • X
  • LinkedIn
  • Instagram

  • NHP Haemoglobinopathy England
  • Sickle Cell Thalassaemia
  • Rare Inherited Anaemia UK

Website Design by Webfactory